Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis.

This study compared real-world treatment patterns and healthcare costs among biologic-naive patients with PsA initiating apremilast or biologics. Methods: A retrospective cohort study was conducted using the Optum Clinformatics™ claims database. The study included biologic-naive patients with PsA who initiated treatment with apremilast or a biologic between January 1, 2014, and December 31, 2015. Propensity score matching was used to adjust for selection bias. Treatment persistence/adherence and all-cause healthcare costs were evaluated. Cost differences were determined using Wilcoxon rank-sum tests. Results: In all, 125 biologic-naive patients initiating treatment with apremilast were matched to 245 biologic-naive patients initiating treatment with a biologic. Twelve-month treatment persistence was similar for apremilast versus biologic users (43.2% vs 36.7%; P = 0.2277). While persistent on treatment for up to 12 months, total healthcare costs (from all utilizations) were significantly lower among apremilast versus biologic users ($28,130 vs $37,093; P 
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research

Related Links:

AbstractBackgroundInformation on the factors that influence treatment management decisions for psoriatic arthritis (PsA) is limited.ObjectiveOur objective was to evaluate the impact of clinical specialty setting and geographic region on the management of patients with PsA in the USA.MethodsLOOP was a multicenter, cross-sectional, observational study conducted across 44 sites in the USA. Patients were aged  ≥ 18 years with a suspected or established diagnosis of PsA and were routinely visiting a rheumatologist or dermatologist. All patients enrolled in the study were assessed by both a rheumatologist a...
Source: American Journal of Clinical Dermatology - Category: Dermatology Source Type: research
AbstractDiet is a modifiable factor implicated in chronic systemic inflammation, and the mediterranean dietary pattern is considered to be a healthy model in terms of morbidity and mortality. The main aim of this study was to evaluate the adherence to the mediterranean diet in patients with Psoriatic Arthritis (PsA) and its impact on disease activity. A cross-sectional observational study was conducted in a cohort of 211 consecutive PsA patients. We evaluated PsA activity by disease activity index for PSoriatic Arthritis (DAPSA) and composite psoriatic disease activity index (CPDAI). The NCEP-ACT III criteria were used to ...
Source: Rheumatology International - Category: Rheumatology Source Type: research
By the time you read this blog, two or three people will have taken their lives. In fact, every 40 seconds someone completes suicide; Close to 800,000 die by suicide every year. According to the World Health Organization, there are more deaths from suicide than from war and homicide together. Suicide is the second leading cause of death between people ages 15 to 29. These statistics don’t surprise me since I’ve lost two family members and several friends to suicide, and about one third of the people I know have lost a loved one to suicide. I am familiar with the desperation and rationale that leads someone to t...
Source: World of Psychology - Category: Psychiatry & Psychology Authors: Tags: Depression Suicide World Mental Health Day Suicidal Thoughts Source Type: blogs
In this study, we aimed to identify an AS case which has AS ‐originated pathological changes on a relatively well‐preserved middle‐aged male skeleton, recovered from the archaeological excavation of Kılıçlı Church, Sinope, Northern Turkey and dated to the 18‐19th centuries. In addition, we made a differential diagnosis with other pathologies such as diffuse idiopathic skeletal hyperostosis (DISH), reactive arthritis (ReA), and psoriatic arthritis (PsA). In the specimen there are four macroscopic features which are diagnostic of AS: (1) both sacroiliac joints were symmetrically obliterated, (2) spinal fusi...
Source: International Journal of Osteoarchaeology - Category: Science Authors: Tags: RESEARCH ARTICLE Source Type: research
Abstract OBJECTIVE: The aim of this study was to compare patients with ankylosing spondylitis with psoriasis (ASP) and without psoriasis (AS), to axial PsA (axPsA) patients. METHODS: Two adult cohorts were recruited from the AS clinic: ASP and AS. These two cohorts were compared with two adult cohorts recruited from the PsA clinic: axPsA (radiographic sacroiliitis: ⩾bilateral grade 2 or unilateral grade 3 or 4); and Peripheral PsA. All patients were followed prospectively according to the same protocol. The demographic, clinical and radiographic variables were compared. Adjusted means were used to account f...
Source: Pain Physician - Category: Anesthesiology Authors: Tags: Rheumatology (Oxford) Source Type: research
Accurately classifying patients with psoriatic arthritis (PsA) can be difficult, especially patients with monoarticular/oligoarticular and polyarticular forms of PsA. A session at the 2019 European Congress of Rheumatology provided insight into the assessment and treatment of PsA subtypes...
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Conditions EULAR Psoratic Arthritis skin Source Type: research
Conclusion: While tofacitinib has a wide array of immunoregulatory properties, making it a possible candidate for treating many dermatologic conditions refractory to other treatments, further testing is needed to better characterize its efficacy and utility moving forward, as well as its safety and adverse effect profile. PMID: 31581859 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
Condition:   Psoriatic Arthritis Interventions:   Drug: Filgotinib;   Drug: Placebo to match filgotinib Sponsors:   Gilead Sciences;   Galapagos NV Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Condition:   Psoriatic Arthritis Interventions:   Drug: Filgotinib;   Drug: Adalimumab;   Drug: Placebo to match filgotinib;   Drug: Placebo to match adalimumab Sponsors:   Gilead Sciences;   Galapagos NV Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Condition:   Psoriatic Arthritis Interventions:   Drug: Filgotinib;   Drug: Placebo to match filgotinib Sponsors:   Gilead Sciences;   Galapagos NV Not yet recruiting
Source: - Category: Research Source Type: clinical trials
More News: Arthritis | Databases & Libraries | Healthcare Costs | Psoriatic Arthritis | Research | Rheumatology | Study